Voyager Therapeutics (VT6) Stock Forecast & Price Target
VT6 Analyst Ratings
Strong Buy
5Buy0Hold0Sell
Based on 5 analysts giving stock ratings to Voyager Therapeutics in the past 3 months
VT6 Stock 12 Month Forecast
Average Price Target
EUR 12.31▲(709.98% Upside)Based on 5 Wall Street analysts offering 12 month price targets for Voyager Therapeutics in the last 3 months. The average price target is EUR 12.31 with a high forecast of EUR 22.38 and a low forecast of EUR 7.16. The average price target represents a 709.98% change from the last price of EUR 1.52.
Past 12 Months12 Month ForecastJan2026Oct2026
HighEUR 22.38
AverageEUR 12.31
LowEUR 7.16
Highest Price TargetHighestEUR 22.38Average Price TargetEUR 12.31Lowest Price TargetLowestEUR 7.16
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Patrick Trucchio | H.C. Wainwright | EUR 22.38 | buy | 1372.69%Upside | Reiterated | 10/28/26 | ||
| Sumant Kulkarni | Canaccord Genuity | EUR 10.74 | buy | 606.89%Upside | Reiterated | 10/23/26 | ||
 Unknown AnalystNot Ranked | Wells Fargo | EUR 8.95 | buy | 489.08%Upside | Reiterated | 10/02/26 | ||
| Yun Zhong | Wedbush | EUR 7.16 | buy | 371.26%Upside | Reiterated | 08/07/26 | ||
| Phil Nadeau | TD Cowen | ― | buy | ― | Reiterated | 08/06/26 | ||
| Debjit Chattopadhyay | Guggenheim | EUR 19.70 | buy | 1195.97%Upside | Reiterated | 06/02/26 | ||
| Unknown AnalystNot Ranked | Oppenheimer | EUR 16.12 | buy | 960.34%Upside | Reiterated | 05/08/26 | ||
| Samantha Semenkow | Citi | EUR 9.85 | buy | 547.99%Upside | Reiterated | 03/23/26 | ||
| Joon Lee | UBS | ― | buy | ― | Reiterated | 03/17/26 | ||
| Lili (Aurélie) Nsongo | Leerink Partners | EUR 9.85 | buy | 547.99%Upside | Reiterated | 12/15/25 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Patrick Trucchio | 10/28/26 | EUR 22.38 | buy | 1372.69%Upside | Reiterated | H.C. Wainwright | ||
| Sumant Kulkarni | 10/23/26 | EUR 10.74 | buy | 606.89%Upside | Reiterated | Canaccord Genuity | ||
| Unknown AnalystNot Ranked | 10/02/26 | EUR 8.95 | buy | 489.08%Upside | Reiterated | Wells Fargo | ||
| Yun Zhong | 08/07/26 | EUR 7.16 | buy | 371.26%Upside | Reiterated | Wedbush | ||
| Phil Nadeau | 08/06/26 | ― | buy | ― | Reiterated | TD Cowen | ||
| Debjit Chattopadhyay | 06/02/26 | EUR 19.70 | buy | 1195.97%Upside | Reiterated | Guggenheim | ||
| Unknown AnalystNot Ranked | 05/08/26 | EUR 16.12 | buy | 960.34%Upside | Reiterated | Oppenheimer | ||
| Samantha Semenkow | 03/23/26 | EUR 9.85 | buy | 547.99%Upside | Reiterated | Citi | ||
| Joon Lee | 03/17/26 | ― | buy | ― | Reiterated | UBS | ||
| Lili (Aurélie) Nsongo | 12/15/25 | EUR 9.85 | buy | 547.99%Upside | Reiterated | Leerink Partners |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Voyager Therapeutics
3 Months
Success Rate7/19 ratings generated profit
37%
Average Return
+0.54%
Copying Debjit Chattopadhyay's trades and holding each position for 3 Months would result in 36.84% of your transactions generating a profit, with an average return of +0.54% per trade.
1 Year
Success Rate11/28 ratings generated profit
39%
Average Return
-18.87%
Copying Sumant Kulkarni's trades and holding each position for 1 Year would result in 39.29% of your transactions generating a profit, with an average return of -18.87% per trade.
2 Years
Success Rate2/28 ratings generated profit
7%
Average Return
-34.08%
Copying Sumant Kulkarni's trades and holding each position for 2 Years would result in 7.14% of your transactions generating a profit, with an average return of -34.08% per trade.
VT6 Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 13 | 12 | 10 | 9 | 4 |
| Buy | 3 | 3 | 2 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 16 | 15 | 12 | 10 | 4 |
In the current month, VT6 has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. VT6 average Analyst price target in the past 3 months is 12.31.
VT6 Financial Forecast
HighEUR -0.25
ConsensusEUR -0.37
LowEUR -0.72
VT6 Earnings Forecast
Next quarter’s earnings estimate for VT6 is -EUR 0.37 with a range of -EUR 0.72 to -EUR 0.25. The previous quarter’s EPS was -EUR 0.36. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighEUR 13.4M
ConsensusEUR 5.68M
LowEUR 27.7K
VT6 Sales Forecast
Next quarter’s sales forecast for VT6 is EUR 5.68M with a range of EUR 27.72K to EUR 13.41M. The previous quarter’s sales results were EUR 2.83M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
VT6 Stock Forecast FAQ
What is DE:VT6’s average 12-month price target, according to analysts?
Based on analyst ratings, Voyager Therapeutics’s 12-month average price target is €12.31.
What is DE:VT6’s upside potential, based on the analysts’ average price target?
Voyager Therapeutics has 709.98% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Voyager Therapeutics a Buy, Sell or Hold?
Voyager Therapeutics has a consensus rating of Strong Buy, which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
What is Voyager Therapeutics’s share price target?
The average share price target for Voyager Therapeutics is €12.31. This is based on 5 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €22.38, and the lowest forecast is €7.16. The average share price target represents a 709.98% increase from the current price of €1.52.
What do analysts say about Voyager Therapeutics?
Voyager Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Street analysts.
How can I buy shares of Voyager Therapeutics?
To buy shares of DE:VT6, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
